Biotech and Medtech VC funds

Bpifrance operates several venture capital funds dedicated to Biotech and Medtech companies.

Presentation

Innobio is a €173m venture capital fund launched in 2009 focused on early- and mid-stage biotech and medtech start-ups. Its LPs are Bpifrance and nine major pharmaceutical companies. It invests in the development of the most promising French life sciences start-ups up to an IPO or a strategic partnership with a major pharmaceutical/medtech company. The team focuses on multiple therapeutic areas including oncology, rare diseases, cardiovascular, diabetes, neurology/ophthalmology and inflammatory / infectious diseases.

Innobio 2, launched in 2019, is Innobio’s successor fund. It just made its first closing at €135m with a goal to achieve €200+m. It is also focused on the development of the most promising Biotechnology start-ups investing up to €14m alongside VCs in Series A and B rounds with the ability to participate in follow-on rounds of financing. It focuses on France with the capacity to invest up to 25% in other European countries.

The Rare Diseases Fund is a €50m venture capital fund launched in 2014. It focuses on early stage Biotechnology companies active in the rare diseases space. The fund was 40% subscribed by the FNA (a “Programme d’Investissement d’Avenir” Fund) and 60% subscribed by AFM-Téléthon, the French muscular dystrophy charity.

The Medtech innovation Fund is a €150m venture capital fund launched in 2014. It focuses on early to mid- stage medtech and diagnostic companies. The fund is fully subscribed by Bpifrance.
Bpifrance manages other Life Sciences funds that are now virtually closed to new investments including the Fonds Accélération Biotech Santé (FABS), PSIM, etc.

Patient Autonome is a venture capital fund focusing on new uses with high medical value that will revolutionise medicine: diagnosis (Artificial Intelligence, deep/machine learning), real-time disease monitoring, patient treatment (remote consultation and follow-up), efficiency of the patient’s care path. Its mission is to detect new uses and support their fast and sustainable launch on their market, after an efficient structuring. With €50m under management, the Patient Autonome fund aims to identify and develop the most promising French start-ups in connected health, at the seed stage.
 

Contact

Laurent Arthaud

Managing Director for Lifesciences, Ecotechnologies and French Tech

Mail : laurent.arthaud@bpifrance.fr